Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Open Label Study to Evaluate Effectiveness and Safety of AdCMV-p53 Administered by Intra-Tumoral Injections in 39 Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT00003257 is registered in ClinicalTrials.gov with Aventis Pharmaceuticals as lead sponsor.

NCT NCT00003257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Open Label Study to Evaluate Effectiveness and Safety of AdCMV-p53 Administered by Intra-Tumoral Injections in 39 Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor
Aventis Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 1998
Completion date
Not reported
Enrollment
39 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer